Ambrx Biopharma Inc.
NYSE:AMAM
28 (USD) • At close March 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Ambrx Biopharma Inc. |
Symbool | AMAM |
Munteenheid | USD |
Prijs | 28 |
Beurswaarde | 1,772,097,600 |
Dividendpercentage | 0% |
52-weken bereik | 6.55 - 28.15 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Daniel J. O'Connor J.D. |
Website | https://ambrx.com |
An error occurred while fetching data.
Over Ambrx Biopharma Inc.
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)